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Background: The purpose of the study was to evaluate the effect of radiation therapy and chemoradiation with
gemcitabine (GEM) after R1 resection in patients with pancreatic adenocarcinoma (PAC).
Methods: We performed a retrospective analysis of 25 patients who were treated with postoperative radiotherapy
(RT) or chemoradiation (CRT) after surgery with microscopically positive resection margins for primary pancreatic
cancer (PAC). Median age was 60 years (range 34 to 74 years), and there were 17 male and 8 female patients.
Fractionated RT was applied with a median dose of 49.6 Gy (range 36 to 54 Gy). Eight patients received additional
intraoperative radiotherapy (IORT) with a median dose of 12 Gy.
Results: Median overall survival (mOS) of all treated patients was 22 months (95% confidence interval (CI) 7.9 to
36.1 months) after date of resection and 21.1 months (95% CI 7.6 to 34.6 months) after start of (C)RT. Median
progression-free survival (mPFS) was 13.0 months (95% CI 0.93 to 25 months). Grading (G2 vs. G3, P = 0.005) and
gender (female vs. male, P = 0.01) were significantly correlated with OS. There was a significant difference in mPFS
between male and female patients (P = 0.008). A total of 11 from 25 patients experienced local tumour progression,
and 19 patients were diagnosed with either locoregional or distant failure.
Conclusions: We demonstrated that GEM-based CRT can be applied in analogy to neoadjuvant protocols in the
adjuvant setting for PAC patients at high risk for disease recurrence after incomplete resection. Patients undergoing
additive CRT have a rather good OS and PFS compared to historical control patient groups.
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Most patients suffering from pancreatic adenocarcinoma
(PAC) may not undergo a curative resection because of
either locally advanced disease associated with lymph
node invasion or disseminated disease [1,2]. Therefore,
only about 10% to 20% of all tumours can be resected,
and even resected patients show a median survival of 10
to 40 months in newer cohorts [3]. The standard therapy
for PAC is a surgical complete resection, but long-term
survival of affected patients is still bad. Over the last de-
cades, an improvement of surgical techniques has been* Correspondence: daniel.habermehl@tum.de
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unless otherwise stated.stated with a survival advantage for patients undergoing
pancreaticoduodenectomy [3]. Even if surgery was well
performed with negative resection margins, patients
would still have a high risk of locoregional and distant
tumour recurrence [4,5]. A recent large monoinstitutional
review of patients undergoing adjuvant chemoradiation
(CRT) reports a recurrence rate of 87% in all patients, with
55% of all patients experiencing a locoregional relapse
(local, peritoneal) [6]. There was no difference in survival
between R0- and R1-resected patients. Further reports on
the influence of complete and incomplete resections on
survival are conflicting. Brennan and colleagues invented a
nomogram with risk factors influencing survival after
multivariate analysis (tumour size, nodal status, need for
splenectomy, grade, tumour localization, posterior margintral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Table 1 Patient characteristics
Patient characteristics Values
Number 25
Gender
Male 17 (68%)
Female 8 (32%)
Age (years)
Median, range 60 (34 to 74)
Localization
Head 21
Body and/or tail 4
Lymph node status
Positive 16 (64%)
Negative 9 (36%)
Grading
G1 0
G2 11
G3 11
G4 1
Not reported 2a
RTX
EBRT median dose (range) (n = 26) 49.6 Gy (36 to 54 Gy) RT
IORT median dose (range) (n = 7) IORT: 12 Gy (10 to 15 Gy)
Concomitant CTX
Overall (with gemcitabine) 23 (92%)
None 2 (8%)
Toxicity
Gastrointestinal (I to III°) 17
Haematological (I° to IV°) 17
Grade II 11
Grade III 5
Grade IV 1
Previous tumour resection None
Duration resection - onset of RT
Median, range [days] 44 (12 to 100)
<30 days 5
30 to 50 days 11
>50 days 9
RT radiotherapy, Gy grey, IORT intraoperative radiotherapy, CTX chemotherapy,
EBRT external beam radiotherapy. aExplanation in ‘Patients and methods’ section.
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margin status on survival [7]. In contrast to these findings,
Fusai and colleagues found no significant difference in sur-
vival of R0- and R1-resected patients [8].
However, adjuvant systemic therapy can be seen as
international standard after curative intended surgical re-
section, whereas combined CRT protocols with gemcita-
bine (GEM) or fluorouracil (FU; plus folinic acid (FA)) are
becoming more widely used in the primary setting for
unresectable PAC with encouraging results [9]. An opti-
mal or rather consensus therapy for incomplete resected
patients is not observed [6,9]. In case of complete resected
PAC, many centres especially in Europe administer adju-
vant chemotherapy with FU/FA during a time period of
6 months after surgery according to the large randomized
but controversial phase III ESPAC trial [10,11] or with
GEM [12]. In the US, there is a trend for combined CRT
protocols using FU/FA for the same indication according
to the randomized phase III RTOG 97–04 trial [12] and
large monoinstitutional analyses [13].
However, patient groups were heterogeneous concern-
ing the resection state (R0, R1), and in most trials and
retrospective reviews, there was no difference in survival
between both groups [8,14,15]. The feasibility and efficacy
of combined therapy regimens consisting of radiotherapy
(RT) and GEM were recently demonstrated by the ran-
domized phase III GERCOR trial which examined the out-
come of patients after R0 resection with this protocol [16].
According to our institutional policy, patients with R0
resections are treated with FU/FA, whereas R1-resected
patients are discussed in an interdisciplinary setting. We
have identified a group of 25 patients that underwent
CRT with gemcitabine after incomplete resection or
who were at high risk for recurrence in our institution
during the last decade and present the therapeutic out-
come and tolerance of this homogenously treated pa-
tient cohort.
Methods
Patients and methods
Patient characteristics
From 2001 to 2009, a total of 25 patients underwent post-
operative RT or CRT after surgical resection of PAC. Each
patient was evaluated and discussed in an interdisciplinary
setting with experienced surgeons, radiation oncologists
and oncologists before treatment initiation. All patient
characteristics are shown in Table 1. Patients included in
running clinical trials orchestrated by our centre were ex-
cluded from this analysis, and results are and will be pre-
sented elsewhere.
Surgery and histopathological diagnosis
Evaluation of the histopathological resection status, TNM
status as well as AJCC staging and histological gradingwas performed according to the criteria recommended by
the WHO (2010) [17]. All histological slices were re-
evaluated for this analysis by a pathologist with high ex-
pertise in that field. Resection margins were prepared and
analysed according to a detailed pathological procedure
described by Esposito et al. [18]. Therefore, R1 was defined
Figure 1 Kaplan-Meier curve representing patients’ overall survival.
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was less or equal 1 mm.
Radiation and chemotherapy
For treatment planning, CT imaging was performed ac-
cording to an in-house standard protocol in supine pos-
ition. 3-D treatment planning was performed in 22 patients
and intensity-modulated radiation therapy (IMRT) using
either step-and-shoot or helical (tomotherapy) radiotherapy
in 3 patients, defining two treatment areas: Clinical target
volume (CTV) included the initial pre-operative macro-
scopic tumour extension and relevant regional lymph node
areas (elective nodal irradiation (ENI)). For the planning
target volume (PTV), a safety margin of approximately 10
to 15 mm was added to the CTV and was dependent on
setup accuracy and respiratory motion. Median PTV vol-
ume was 497 ccm (range 223 to 1,400 ccm). In 11 patients,
an additional boost volume was defined if appropriate and
included the area of initial macroscopic tumour extension
with a small safety margin (PTV_boost). Median PTV_boost
volume was 98 ccm (range 38 to 260 ccm).
None of the analysed patients had a history of abdom-
inal RT. One patient (3%) had a history of previous
chemotherapy with gemcitabine (GEM) before surgery.
Ninety-two percent of all patients undergoing RT re-
ceived concurrent chemotherapy with GEM with a dose
of 300 mg/m2 weekly, followed by adjuvant cycles of
full-dose GEM (1,000 mg/m2). Additionally, 14 patients
(54%) received full-dose GEM after completion of CRT.
Before application of GEM, blood values were examined
at the day of treatment or 1 day before and leucocytes
had to be ≥3,000/μl and platelets ≥100,000/μl. Further-
more, physical examination was performed, and there
had to be no evidence of severe infection. During com-
bined CRT and during the adjuvant cycles, blood cell
count and a physical examination were conducted weekly.
Fractionated RT was applied with a median dose of
49.9 Gy (range 36 to 54 Gy) in median single fractions of
1.8 Gy, including dose for image guidance (IGRT). Seven
patients received additional intraoperative radiotherapy
(IORT) with a median dose of 12 Gy (range 10 to 15 Gy)
during surgical resection. In these cases, indication for IORT
was decided by the surgical team and was usually performed
if resection margins were expected to be positive for residual
tumour tissue. However, this was left to the discretion of the
treating surgeon and depended on individual patient and
tumour characteristics during resection. Patients that previ-
ously underwent IORT received a lower median external
beam radiotherapy (EBRT) dose of 41.4 Gy compared to
patients without IORT (median dose 50.4 Gy).
Follow-up and statistics
Four to 6 weeks after completion of chemoradiation and
after 1 cycle of full-dose GEM evaluation of treatmentresponse and assessment of resectability were performed.
In most patients, contrast-enhanced CT or MR imaging
was conducted. Additionally, follow-up visits including
clinical examination as well as tumour marker analysis
were performed. The images as well as the clinical per-
formance status of the patients were evaluated.
Overall survival was calculated from the first day of ir-
radiation until death. Progression-free survival (PFS) was
calculated from the first day of radiotherapy until progres-
sion of disease (local or distant metastasis). The log-rank
test was implemented to compare survival curves evaluat-
ing the association between clinical variables of interest
and survival. All calculations were performed using statis-
tical software program SPSS 18.0 for Windows (Chicago,
Illinois, USA). The comparison to historical data was
drawn from data published in the literature, no formal
comparison of Kaplan-Meier data was performed.
Results
Survival
Median age was 60 years (range 34 to 74 years), and there
were 17 male (68%) and 8 (32%) female patients. Median
overall survival (mOS) of all treated patients was 22 months
(95% confidence interval (CI) 7.9 to 36.1 months) after date
of resection and 21.1 months (95% CI 7.6 to 34.6 months)
after start of CRT (Figure 1). Potential prognostic factors
such as applied IORT (P = 0.85), dose of fractionated RT
(dose ≤45 vs. >45 Gy, P = 0.08), duration from date of sur-
gery until first day of CRT (<30 days, 30 to 50 day, >50 days,
P > 0.05), positive resected lymph nodes (P = 0.89) and
localization (pancreatic head vs. body, P = 0.58) and age
(≤55 vs. >55 years; P = 0.35) were evaluated. None of these
parameters had a significant influence on OS, only grad-
ing (G2 vs. G3, P = 0.005) and gender (female vs. male,
P = 0.01) were significantly correlated with OS (Figure 1).
Figure 3 Kaplan-Meier curve for patients’ local control.
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Main localization of the tumour was the pancreatic head
or body and tail in 21 (84%) and 4 (16%). Median time
from surgery until start of CRT was 41 days (range 12 to
100 days). Positive lymph nodes were diagnosed in 16
patients (64%) whereas 9 (36%) patients had negative
nodes. Histopathological grading was classified G2, G3
and G4 in 11 (44%), 11 (44%) and 1 (4%) patients, re-
spectively. In 2 patients (8%), no information on grading
was achievable due to missing information from external
institutions.
Median progression-free survival was 13.0 months (95%
CI 0.93 to 25 months) (Figure 2). No significant correlation
was found between PFS and IORT (P = 0.85), tumour
localization (P = 0.7), grading (P = 0.3), nodal status (0.4),
duration between resection and RT onset (P = 0.9), age
(P = 0.8) and dose (≤45 vs. >45 Gy) (P = 0.2). There was
a significant difference in median time of progression-
free survival between male and female patients (0.008),
in favour of women.
Median local control according to Kaplan-Meier esti-
mates was 27 months (95% CI 8.1 to 45.9 months) since
start of combined or single modality (C)RT (Figure 3). A
total of 11 from 25 patients (44%) experienced local tumour
progression. Analysis of potentially associated treatment-
related factors showed no influence of IORT (P = 0.78),
patient age (P = 0.96), EBRT (P = 0.1), tumour localization
(P = 0.7), tumour grading (P = 0.09), presence of positive
lymph nodes (P = 0.5) and duration from surgery until RT
onset (P = 0.2) on local disease control. Again, female gen-
der was correlated with a higher local control (P = 0.02).
Nineteen patients (76%) were diagnosed with either
locoregional or distant failure over the course of their
follow-up. Main sites of distant disease progression were
the liver, peritoneum, lungs and bone in 10 (40%), 4
(16%), 1 (4%) and 1 (4%) patients, respectively.Figure 2 Kaplan-Meier curve for patients’ progression-free survival.Toxicity
In general, observed side effects were mild, and thus, no
treatment-related deaths occurred. Seventeen patients had
moderate gastrointestinal toxicity (grade I to III), mainly
consisting of nausea, vomiting, diarrhoea and abdominal
pain. Haematological toxicity consisted mainly of grade II
(12/25 patients, 48%) but also of grade III in 5 (20%) and
grade IV in 1 patient (4%). The side effects could be
treated successfully by supportive care.
Discussion
In our patient cohort with R1 resection and postoperative
administration of GEM-based CRT, mOS of 22 months
postresection could be achieved. The median time to dis-
ease progression was 13 months and consisted mainly of
local progression (44%) and metastasis to the liver (40%).
Nine patients with a local progression had a median time
of 9.9 months until imaging- or surgical-based evidence of
tumour relapse. Median time of local control of all in-
cluded patients was comparably high with estimated
27 months but has limited significance because less than
half of the patients developed local recurrence. Neverthe-
less, there are a considerable high number of patients
without a local tumour progression after 12 months (12
patients) and even after 2 years (6 patients).
During the last years, one large randomized clinical
trial on adjuvant radiotherapy after R0 and R1 resections
was performed at our high-volume centre: results were
recently published [19]. Many patients were therefore in-
cluded in this trial. Moreover, a considerable number of
patients have not received any adjuvant or additive treat-
ment or were treated with systemic agents (for example,
gemcitabine, 5-FU). This may explain the comparable
low number of patients included in our current analysis.
Due to the scarce data in the literature on adjuvant RT
and CRT, the current analysis seems justified.
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the abovementioned large randomized clinical trials which
mainly included patients after R0 resection but also pa-
tients with positive margins, for example, approximately
17% of patients in the CONKO-001 trial [20], 18% in the
ESPAC trial [15] and 35% in the Johns-Hopkins-Mayo col-
laborative experience [13]. A further meta-analysis of five
published randomized clinical trials (RCT) showed a range
of ‘margin positive’ resections of 0% to 83% with a median
of 23% [14]. Compared to the reported overall outcome of
the mentioned trials as well as to the subgroups of R1/R2-
resected patients, the mOS achieved in this study (with a
standardized histopathological protocol) seems to be at
least equieffective. The CONKO-001 group reports a R1
subgroup-specific mOS of 22.1 months (GEM group and
R1-resected), the ESPAC trialists present an mOS of 15.9
in the CRT group and the bi-institutional study from Hsu
and colleagues reports a mOS of 15.1 months for R1/R2-
resected patients after CRT. The meta-analysis of Buttur-
ini et al. revealed a mOS of 14.7 months for the subgroup
of patients with R1 resection and after adjuvant CRT.
Long-term survival after curative intended resection
for PAC has been described by a recent case–control
study from the Mayo Clinic [21]. Schnelldorfer et al.
analysed 357 patients, of which a total of 62 (17%) sur-
vived at least 5 years and further 21 (6%) were alive even
10 years after treatment. The median survival times were
18, 15 and 10 months after R0, R1 and R2 resections, re-
spectively. A multivariate analysis on prognostic factors
showed that resection margin is not an independent
prognostic factor. In our analysis, we found 9 patients
(36%) that were still alive for at least 2 years, taking into
account a comparable short mean follow-up period of
21 months.
Until now, there exists no international standardized ad-
juvant or additive therapy after resection of PAC. European
institutions tend to use postoperative chemotherapy proto-
cols mainly containing full-dose GEM for six cycles mainly
based on the large randomized CONKO-001 trial [20] or
FU/FA as tested in the ESPAC trials [11,15] whereas CRT
protocols including FU/FA are rather established in the US
according to large monoinstitutional experiences [13]. The
approach of our institution in patients with residual disease
or at high risk of tumour recurrence is a GEM-containing
CRT which has proven efficacy in neoadjuvant, recurrent
and adjuvant biliary and pancreatic disease [4,9,22]. Recent
approaches have also evaluated the potential benefit of a
more aggressive systemic agent regime including interferon
(IFN) α-2b [19]. For this purpose, 132 R0/R1-resected pa-
tients received either FU, cisplatin, and IFN α-2b concomi-
tant with RT followed by two cycles of FU (arm A, n = 64)
or six cycles of FU monotherapy (arm B, n = 68). Median
survival for all randomly assigned patients was comparable
in both arms (26.5 and 28.5 months in arms A and B,respectively). Although median survival was very good in
both arms, substantial therapy-related higher toxicities
grades III and IV were recorded in as many as 85% and
16% in arms A and B, respectively.
Defining the R1 resection status as well as its significance
on survival is still a matter of debate among specialists. Pa-
tients recruited in the abovementioned large trials were usu-
ally not stratified according to the extent of resection and
clearly vary in the number of R1 resections [14]. The signifi-
cance of clear resection margins compared to R1 resections
was indeed emphasized by different groups, but other
groups failed to find differences in survival times between
R0- and R1-resected patients, or difference was small
[8,23,24]. A possible explanation of these conflicting findings
is a difference in the definition of an R1 resection, and thus,
the pathological assessment of the specimen after pancreati-
coduodenectomy which significantly varies among centres
and mirrors a lack of international consensus [25,26].
Whereas some centres define the R1 resection according to
the ‘old’ rule that microscopic tumour cells must invade the
resection border, others classify even a distance up to 1 mm
to the border as R1 [25]. As a consequence of this high
variability in resection margin definition among centres, it
has to be assumed that R1 resections are clearly underrep-
resented in published studies according to Verbeke and
Chang et al. [25,27]. Recently, an important approach on
that issue was undertaken by Chang and co-workers who
examined in detail the relationship between margin clear-
ance and outcome in 365 PAC patients after curative-
intended surgery [27]. Patients were divided into different
subgroups depending on the extend of tumour resection/
margin clearance (0 to 0.5 mm, 0.5 to 1 mm, 1 to 1.5 mm
and greater than 1.5 mm). Influence of the margin clear-
ance on locoregional disease recurrence, median survival
and especially long-term survival was analysed. Surpris-
ingly, there was no difference detected in mOS between pa-
tients with a directly involved resection margin and those
who had a margin clearance of more than 1.5 mm, but
long-term survival was better in the latter group. Finally,
patients after R1 resection are at different risk levels for dis-
ease recurrence or disease progression. Whereas all PAC
patients are at high risk to have an occult metastatic disease,
there may be a higher risk for locoregional recurrence/pro-
gression in patients with a higher postsurgical tumour load
depending on margin clearance, thus advocating a local
radiotherapy. Patients with clear margins have a relatively
higher risk of developing distant metastatic disease and may
therefore benefit more from a systemic chemotherapy. This
has been shown in a meta-analysis of Stocken et al. where
patients with R0 resection had the most benefit from adju-
vant chemotherapy compared to patients with residual
microscopic tumour residues [28]. According to these find-
ings, one may hypothesize that patients with a closer resec-
tion of 0.5 mm have a higher probability to benefit from an
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light of the comparably superior outcome of our R1-
resected patient cohort, one may hypothesize that many
of the included specimens would be classified as R0 in
other centres with less strict protocols with the corre-
sponding implication of improved survival times.
Female gender was positively correlated with PFS and
OS in our analysis. Recent reports on prognostic factors
of PAC patients undergoing adjuvant or additive treatment
are differing. Population-based and other large retrospective
analyses failed to identify gender as a prognostic factor in
patient groups undergoing adjuvant treatments [13,29,30].
However, Redmond and co-workers from Johns Hopkins
University found that female gender has prognostical bene-
fit in terms of improved OS in a monoinstitutional analysis
of patients undergoing adjuvant 5FU-based CRT [31].
GEM-based regimens become more widely used in hepa-
tobiliary and pancreatic cancer because of its efficacy and
good tolerability [4,9,16,22,32,33]. Toxicity rates were com-
parable to data derived from larger reports and clinical trials.
We observed a grade III or higher haematological toxicity in
24% of all patients. This percentage is comparable to the
ESPAC-3 study where 22% of the patients in the FU + FA
and the GEMgroup experienced grade III/IV toxicities (neu-
trophil count) and the GERCOR study where 33% of the
patients in the combined GEM-containing CRTgroup expe-
rienced grade III/IV toxicity (neutrophil count) [16,34].
Our retrospective analysis is the first report to our
knowledge on adjuvant GEM-based CRT for PAC patients
after R1 resection, with the latter being confirmed by a
standardized pathological procedure [18]. The study has
mentionable limitations, mainly based on a low number of
patients included, the non-randomized character as well
as the difficult comparison to heterogeneous historical
collectives. However, considering the few publications in
this clinical setting and the difficult decision-making in in-
dividual clinical situations even in high-volume centres,
the data can be cited as useful treatment recommendation
in certain clinical situations. GEM-based CRT is effective
and feasible and can be applied in analogy to neoadjuvant
protocols at our institution [4,9]. Survival was surprisingly
good and nearly a third of all patients being still alive after
more than 24 months.
According to international guidelines, RT is no standard
adjuvant treatment after resection but is chemotherapy.
However, after interdisciplinary discussion, indication for
adjuvant CRT is decided upon in certain cases. Further
randomized clinical trials are needed to identify patients
that benefit most from an intensified local and systemic
therapy in the postoperative setting.
Conclusions
This work demonstrates that GEM-based CRT can be ap-
plied in analogy to neoadjuvant protocols in the adjuvantsetting for PAC patients at high risk for disease recurrence
after incomplete resection. Overall survival and progression-
free survival times are considerably high compared to histor-
ical control patient groups.
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